Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021

Sep 29, 2021

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference

Sep 27, 2021

Acurx Pharmaceuticals to Join the Russell Microcap Index®

Sep 2, 2021

Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Aug 31, 2021

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update

Aug 16, 2021

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021

Aug 12, 2021

Acurx Pharmaceuticals Joins the Antimicrobials Working Group

Aug 5, 2021

Health Holland Awards Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Aug 2, 2021

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update

Jul 28, 2021

Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome

Jul 7, 2021